Injectable weight loss drugs

A new weight-loss treatment, Tirzepatide (Mounjaro), is being introduced on the NHS to support individuals living with obesity. It will join the existing range of injectable medications, including Wegovy (semaglutide) and Saxenda (liraglutide).

This announcement, alongside media reports that GPs may begin prescribing these treatments from 23 June 2025, has understandably generated a great deal of public interest. As a result, we are receiving a high volume of enquiries.

Due to the ongoing pressure on general practice resources, we kindly ask that patients refer to this page for the latest information rather than contacting the practice directly. We will continue to provide updates here as more details become available.

Our position 

While it is true that Primary Care is expected to play a role in delivering these injections at some point in the future, this does not necessarily mean they will be provided by general practice specifically, it could involve other parts of the wider primary care system. If general practice were to be involved, clear pathways, appropriate training, and support structures would first need to be established to ensure the treatment is delivered safely and appropriately to patients.

To put numbers into context, it is expected 220,000 patients across the UK will be eligible for the injection, this translates into approximately less than 100 patients of Pathfields from the 30,000 population. 

We will share any updates or developments here as soon as they become available here. 

Private prescribing

• NHS services are currently unable to support patients who buy weight loss injections nor our we able to advise on a safe place to buy weight loss injections.
• We are aware that there are private providers who offer Tirzepatide, please be aware that some people may experience side effects, which may not be safely monitored by non-NHS providers. The private provider should offer a wrap-around service to support patients, and we would recommend that patients engage with this.

Referrals to Oviva

Oviva, a provider of digitally enabled weight management programmes, are actively publicising their Tier 3 Digital Weight Management Service, inclusive of GLP-1 medication prescribing. They are now accepting referrals from all GP in England under the Right to Choose Framework which we can refer eligible patients to.

Eligibility:

Age 18 or older, registered with a GP in England or specific NHS regions

Body Mass Index (BMI):

• ≥ 40, or
• ≥ 35 with at least one weight‑related comorbidity (e.g. type 2 diabetes, hypertension, asthma, depression, heart disease, PCOS, sleep apnoea, gallbladder issues, acid reflux)
• For people from certain ethnic minority backgrounds, the BMI threshold for comorbidities may be ≥ 27.5–32.5

Note – there is also exclusion criteria.

If you meet this criteria, and would like to discuss a potential referral please submit a referral from via our online consultation - Online Consulting 'Adults online consulting' - 'Other medical request' - Oviva weight loss referral screening' A clinician will assess your eligibility for an onward referral. Please note if you are eligible you will need to attend the surgery for a weight, blood pressure and blood test to accompany the referral.